Among the drugs for ophthalmic diseases, anti-VEGF drugs are developing rapidly, and aflibercept is amplified rapidly. At the same time, the development of new targets, new drug delivery methods and bispecific antibodiesRead More…
1. Nat Biotechnol: Edible antibody molecules contribute to the treatment of gastrointestinal diseases Therapeutic antibodies are increasingly used clinically to treat a variety of diseases. However, oral gut-targeted antibodies remain a challenge becauseRead More…
In 2018, Loxo Oncology’s “unlimited cancer” targeted therapy Vitrakvi was approved by FDA, becoming the first targeted therapy for patients with NTRK gene fusion variant solid tumors. Loxo, on the other hand,Read More…
Kyowa Hakko Kirin announced submission of Crysvita (burosumab, KRN23) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of FGF-23-related hypophosphatemic rickets and osteomalacia. The active ingredient ofRead More…
Currently, the Scripps Research Institute has developed a new candidate AIDS vaccine that can effectively overcome the technical barriers of previous AIDS vaccines and stimulate powerful anti-HIV antibody responses in animal experiments.Read More…
HIV evades the body’s immune defenses through multiple mutations, and the antibodies against HIV produced by the host’s immune system follow a complex and difficult-to-track evolutionary pathway. This complexity makes it difficultRead More…
Kyowa Hakko Kirin, a Japanese pharmaceutical company, recently announced that the European Commission (EC) has approved Poteligeo (mogamulizumab) to treat adult patients with relapsed or refractory mycosis fugoides (MF) or Sezary syndromeRead More…
In the past decade, tumor immunotherapy has overturned the traditional concept of treatment, especially the discovery and application of immune checkpoint molecules. The immune checkpoint can be irritating or inhibitory, and theRead More…